Bioactivity_ID,Protein_Accession,Activity_Type,Activity_Qualifier,Bioassay_Data_Source,BioAssay_Name,Compound_Name,Target_Name,Target_Link,ECs,Representative_Protein_Accession,Cell_ID,Anatomy,dois,pmcids,pclids,citations,BioAssay_AID,Substance_SID,Compound_CID,refsid,Gene_ID,PMID,AidType,Last_Modified_Date,Has_Dose_Response_Curve,RNAi_BioAssay,Activity,Activity_Value,Taxonomy_ID,Target_Taxonomy_ID,Anatomy_ID
383928371,P07949,IC50,=,ChEMBL,Inhibition of human RET V804L mutant,Pralsetinib,RET - ret proto-oncogene (human),/gene/5979,2.7.10.1,P07949,,,10.1021/acs.jmedchem.2c01361,,35285560,"Zhou Y, Xiang S, Yang F, Lu X. Targeting Gatekeeper Mutations for Kinase Drug Discovery. J Med Chem. 2022 Dec 08;65(23):15540–58. doi: 10.1021/acs.jmedchem.2c01361. PMID: 36395392.",1934929,440200762,129073603,483927624,5979,36395392,Confirmatory,20240503,0,0,Active,0.000300,9606,,
381488208,P07949,IC50,=,ChEMBL,Inhibition of recombinant RET V804L (unknown origin) incubated for 120 mins by Perkin Elmer electrophoretic mobility shift platform method,Pralsetinib,RET - ret proto-oncogene (human),/gene/5979,2.7.10.1,P07949,,,10.1021/acs.jmedchem.0c02167,PMC9697126,21703593,"Saha D, Ryan KR, Lakkaniga NR, Acharya B, Garcia NG, Smith EL, Frett B. Targeting Rearranged during Transfection in Cancer: A Perspective on Small-Molecule Inhibitors and Their Clinical Development. J. Med. Chem. 2021 Aug 17;64(16):11747–73. doi: 10.1021/acs.jmedchem.0c02167.",1895756,482048853,129073603,,5979,34402300,Confirmatory,20230629,0,0,Active,0.000300,9606,,
383928134,P07949,IC50,=,ChEMBL,Inhibition of human RET V804M mutant,Pralsetinib,RET - ret proto-oncogene (human),/gene/5979,2.7.10.1,P07949,,,10.1021/acs.jmedchem.2c01361,,35285560,"Zhou Y, Xiang S, Yang F, Lu X. Targeting Gatekeeper Mutations for Kinase Drug Discovery. J Med Chem. 2022 Dec 08;65(23):15540–58. doi: 10.1021/acs.jmedchem.2c01361. PMID: 36395392.",1934930,440200762,129073603,483927624,5979,36395392,Confirmatory,20240503,0,0,Active,0.000400,9606,,
383928178,P07949,IC50,=,ChEMBL,Inhibition of human wild type RET,Pralsetinib,RET - ret proto-oncogene (human),/gene/5979,2.7.10.1,P07949,,,10.1021/acs.jmedchem.2c01361,,35285560,"Zhou Y, Xiang S, Yang F, Lu X. Targeting Gatekeeper Mutations for Kinase Drug Discovery. J Med Chem. 2022 Dec 08;65(23):15540–58. doi: 10.1021/acs.jmedchem.2c01361. PMID: 36395392.",1934928,440200762,129073603,483927624,5979,36395392,Confirmatory,20240503,0,0,Active,0.000400,9606,,
381488324,,IC50,=,ChEMBL,Inhibition of recombinant RET V804M (unknown origin) incubated for 120 mins by Perkin Elmer electrophoretic mobility shift platform method,Pralsetinib,,,,,,,10.1021/acs.jmedchem.0c02167,PMC9697126,21703593,"Saha D, Ryan KR, Lakkaniga NR, Acharya B, Garcia NG, Smith EL, Frett B. Targeting Rearranged during Transfection in Cancer: A Perspective on Small-Molecule Inhibitors and Their Clinical Development. J. Med. Chem. 2021 Aug 17;64(16):11747–73. doi: 10.1021/acs.jmedchem.0c02167.",1895757,482048853,129073603,,,34402300,Confirmatory,20230629,0,0,Active,0.000400,,,
381488344,Q16204,IC50,=,ChEMBL,Inhibition of recombinant CCDC6-RET (unknown origin) incubated for 120 mins by Perkin Elmer electrophoretic mobility shift platform method,Pralsetinib,CCDC6 - coiled-coil domain containing 6 (human),/gene/8030,,Q16204,,,10.1021/acs.jmedchem.0c02167,PMC9697126,21703593,"Saha D, Ryan KR, Lakkaniga NR, Acharya B, Garcia NG, Smith EL, Frett B. Targeting Rearranged during Transfection in Cancer: A Perspective on Small-Molecule Inhibitors and Their Clinical Development. J. Med. Chem. 2021 Aug 17;64(16):11747–73. doi: 10.1021/acs.jmedchem.0c02167.",1895760,482048853,129073603,,8030,34402300,Confirmatory,20230629,0,0,Active,0.000400,9606,,
381488141,P07949,IC50,=,ChEMBL,Inhibition of recombinant RET M918T (unknown origin) incubated for 120 mins by Perkin Elmer electrophoretic mobility shift platform method,Pralsetinib,RET - ret proto-oncogene (human),/gene/5979,2.7.10.1,P07949,,,10.1021/acs.jmedchem.0c02167,PMC9697126,21703593,"Saha D, Ryan KR, Lakkaniga NR, Acharya B, Garcia NG, Smith EL, Frett B. Targeting Rearranged during Transfection in Cancer: A Perspective on Small-Molecule Inhibitors and Their Clinical Development. J. Med. Chem. 2021 Aug 17;64(16):11747–73. doi: 10.1021/acs.jmedchem.0c02167.",1895758,482048853,129073603,,5979,34402300,Confirmatory,20230629,0,0,Active,0.000400,9606,,
381488189,P07949,IC50,=,ChEMBL,Inhibition of wildtype RET (unknown origin) incubated for 120 mins by Perkin Elmer electrophoretic mobility shift platform method,Pralsetinib,RET - ret proto-oncogene (human),/gene/5979,2.7.10.1,P07949,,,10.1021/acs.jmedchem.0c02167,PMC9697126,21703593,"Saha D, Ryan KR, Lakkaniga NR, Acharya B, Garcia NG, Smith EL, Frett B. Targeting Rearranged during Transfection in Cancer: A Perspective on Small-Molecule Inhibitors and Their Clinical Development. J. Med. Chem. 2021 Aug 17;64(16):11747–73. doi: 10.1021/acs.jmedchem.0c02167.",1895755,482048853,129073603,,5979,34402300,Confirmatory,20230629,0,0,Active,0.000400,9606,,
381488345,P07949,IC50,=,ChEMBL,Inhibition of recombinant CCDC6-RET (unknown origin) incubated for 120 mins by Perkin Elmer electrophoretic mobility shift platform method,Pralsetinib,RET - ret proto-oncogene (human),/gene/5979,2.7.10.1,P07949,,,10.1021/acs.jmedchem.0c02167,PMC9697126,21703593,"Saha D, Ryan KR, Lakkaniga NR, Acharya B, Garcia NG, Smith EL, Frett B. Targeting Rearranged during Transfection in Cancer: A Perspective on Small-Molecule Inhibitors and Their Clinical Development. J. Med. Chem. 2021 Aug 17;64(16):11747–73. doi: 10.1021/acs.jmedchem.0c02167.",1895760,482048853,129073603,,5979,34402300,Confirmatory,20230629,0,0,Active,0.000400,9606,,
389414544,P07949,IC50,=,ChEMBL,"Inhibition of His-tagged human recombinant wild type RET M918T mutant expressed in Sf9 cells using poly(Glu, Tyr) peptide as substrate in presence of ATP preincubated fo4 30 mins followed by substrate addition and measured after 1 hr by FRET analysis",Pralsetinib,Proto-oncogene tyrosine-protein kinase receptor Ret (human),/protein/P07949,2.7.10.1,P07949,,,10.1021/acs.jmedchem.3c02319,,36935859,"Wang ZX, Li QQ, Cai J, Wu JZ, Wang JJ, Zhang MY, Wang QX, Tong ZJ, Yang J, Wei TH, Zhou Y, Dai WC, Ding N, Leng XJ, Sun SL, Xue X, Yu YC, Yang Y, Li NG, Shi ZH. Unraveling the Promise of RET Inhibitors in Precision Cancer Therapy by Targeting RET Mutations. J Med Chem. 2024 Mar 28;67(6):4346–75. doi: 10.1021/acs.jmedchem.3c02319. PMID: 38484122.",2091116,440200762,129073603,483927624,,38484122,Confirmatory,20251125,0,0,Active,0.000400,9606,,
374170330,P07949,IC50,=,ChEMBL,Inhibition of RET M918T mutant (unknown origin),Pralsetinib,RET - ret proto-oncogene (human),/gene/5979,2.7.10.1,P07949,,,10.1016/j.bmcl.2021.128149,,2007155,"Luo Z, Wang L, Fu Z, Shuai B, Luo M, Hu G, Chen J, Sun J, Wang J, Li J, Chen S, Zhang Y. Discovery and optimization of selective RET inhibitors via scaffold hopping. Bioorganic & Medicinal Chemistry Letters. 2021 Sep;47():128149. doi: 10.1016/j.bmcl.2021.128149.",1776961,440200762,129073603,483927624,5979,34058344,Confirmatory,20220830,0,0,Active,0.000700,9606,,
374170321,P07949,IC50,=,ChEMBL,Inhibition of RET wild type (unknown origin),Pralsetinib,RET - ret proto-oncogene (human),/gene/5979,2.7.10.1,P07949,,,10.1016/j.bmcl.2021.128149,,2007155,"Luo Z, Wang L, Fu Z, Shuai B, Luo M, Hu G, Chen J, Sun J, Wang J, Li J, Chen S, Zhang Y. Discovery and optimization of selective RET inhibitors via scaffold hopping. Bioorganic & Medicinal Chemistry Letters. 2021 Sep;47():128149. doi: 10.1016/j.bmcl.2021.128149.",1776959,440200762,129073603,483927624,5979,34058344,Confirmatory,20220830,0,0,Active,0.000780,9606,,
385347568,P07949,Kd,=,ChEMBL,Binding affinity to RET (unknown origin) assessed as dissociation constant in presence of ATP by FRET based Z'-Lyte assay,Pralsetinib,RET - ret proto-oncogene (human),/gene/5979,2.7.10.1,P07949,,,10.1016/j.ejmech.2023.115237,,35451621,"Wu K, He R, Li Z, Qiu K, Xiao G, Peng L, Meng X, Zheng C, Zhang Z, Cai Q. Discovery of 3,5-diaryl-1H-pyrazol-based ureas as potent RET inhibitors. European Journal of Medicinal Chemistry. 2023 May;251():115237. doi: 10.1016/j.ejmech.2023.115237.",1995913,404719099,129073603,,5979,36905915,Confirmatory,20250102,0,0,Active,0.001000,9606,,
374169742,P07949,IC50,=,ChEMBL,Inhibition of RET V804M mutant (unknown origin),Pralsetinib,RET - ret proto-oncogene (human),/gene/5979,2.7.10.1,P07949,,,10.1016/j.bmcl.2021.128149,,2007155,"Luo Z, Wang L, Fu Z, Shuai B, Luo M, Hu G, Chen J, Sun J, Wang J, Li J, Chen S, Zhang Y. Discovery and optimization of selective RET inhibitors via scaffold hopping. Bioorganic & Medicinal Chemistry Letters. 2021 Sep;47():128149. doi: 10.1016/j.bmcl.2021.128149.",1776960,440200762,129073603,483927624,5979,34058344,Confirmatory,20220830,0,0,Active,0.001930,9606,,
374169847,O60674,IC50,=,ChEMBL,Inhibition of JAK2 (unknown origin),Pralsetinib,Tyrosine-protein kinase JAK2 (human),/protein/O60674,2.7.10.2,O60674,,,10.1016/j.bmcl.2021.128149,,2007155,"Luo Z, Wang L, Fu Z, Shuai B, Luo M, Hu G, Chen J, Sun J, Wang J, Li J, Chen S, Zhang Y. Discovery and optimization of selective RET inhibitors via scaffold hopping. Bioorganic & Medicinal Chemistry Letters. 2021 Sep;47():128149. doi: 10.1016/j.bmcl.2021.128149.",1776972,440200762,129073603,483927624,,34058344,Confirmatory,20220830,0,0,Active,0.002000,9606,,
383976561,P07949,IC50,=,ChEMBL,Inhibition of wild type rearranged during transfection kinase (unknown origin) preincubated for 1 hr followed by addition of development agent incubated for 1 hr measured by FRET-based Z'-Lyte assay,Pralsetinib,RET - ret proto-oncogene (human),/gene/5979,2.7.10.1,P07949,,,10.1016/j.ejmech.2022.114862,,35235592,"Zhang Y, Chan S, He R, Liu Y, Song X, Tu Z, Ren X, Zhou Y, Zhang Z, Wang Z, Zhou F, Ding K. 1-Methyl-3-((4-(quinolin-4-yloxy)phenyl)amino)-1H-pyrazole-4-carboxamide derivatives as new rearranged during Transfection (RET) kinase inhibitors capable of suppressing resistant mutants in solvent-front regions. European Journal of Medicinal Chemistry. 2022 Dec;244():114862. doi: 10.1016/j.ejmech.2022.114862.",1946834,440200762,129073603,483927624,5979,36308779,Confirmatory,20240503,0,0,Active,0.002400,9606,,
383976861,,IC50,=,ChEMBL,Antiproliferative activity against mouse BaF3 cells expressing rearranged during transfection kinase V804M-CCDC6 incubated for 74 to 76 hrs by cell counting kit 8 method,Pralsetinib,,,,,,,10.1016/j.ejmech.2022.114862,,35235592,"Zhang Y, Chan S, He R, Liu Y, Song X, Tu Z, Ren X, Zhou Y, Zhang Z, Wang Z, Zhou F, Ding K. 1-Methyl-3-((4-(quinolin-4-yloxy)phenyl)amino)-1H-pyrazole-4-carboxamide derivatives as new rearranged during Transfection (RET) kinase inhibitors capable of suppressing resistant mutants in solvent-front regions. European Journal of Medicinal Chemistry. 2022 Dec;244():114862. doi: 10.1016/j.ejmech.2022.114862.",1946835,440200762,129073603,483927624,,36308779,Confirmatory,20240503,0,0,Active,0.003500,,,
373054133,P07949,GI50,<,ChEMBL,Inhibition of KIF5B-RET V804M mutant fusion protein (unknown origin) expressed in mouse BaF3 cells assessed as reduction in cell proliferation measured after 48 hrs by MTS assay,Pralsetinib,RET - ret proto-oncogene (human),/gene/5979,2.7.10.1,P07949,,,10.1016/j.ejmech.2020.112755,,21684558,"Li X, Su J, Yang Y, Lian W, Deng Z, Yang Z, Chen G, Zhang B, Dong C, Liu X, Li L, Wang Z, Hu Z, Xu Q, Deng X. Discovery of 4-methyl-N-(4-((4-methylpiperazin- 1-yl)methyl)-3-(trifluoromethyl)phenyl)-3-((6-(pyridin-3-yl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl)-oxy)benzamide as a potent inhibitor of RET and its gatekeeper mutant. European Journal of Medicinal Chemistry. 2020 Dec;207():112755. doi: 10.1016/j.ejmech.2020.112755.",1704862,440200762,129073603,483927624,5979,32882611,Confirmatory,20250102,0,0,Active,0.004000,9606,,
372230671,P33176,GI50,<,ChEMBL,Inhibition of KIF5B-RET fusion protein (unknown origin) expressed in mouse BaF3 cells assessed as reduction in cell proliferation measured after 48 hrs by MTS assay,Pralsetinib,KIF5B - kinesin family member 5B (human),/gene/3799,,P33176,,,10.1016/j.ejmech.2020.112755,,21684558,"Li X, Su J, Yang Y, Lian W, Deng Z, Yang Z, Chen G, Zhang B, Dong C, Liu X, Li L, Wang Z, Hu Z, Xu Q, Deng X. Discovery of 4-methyl-N-(4-((4-methylpiperazin- 1-yl)methyl)-3-(trifluoromethyl)phenyl)-3-((6-(pyridin-3-yl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl)-oxy)benzamide as a potent inhibitor of RET and its gatekeeper mutant. European Journal of Medicinal Chemistry. 2020 Dec;207():112755. doi: 10.1016/j.ejmech.2020.112755.",1704858,440200762,129073603,483927624,3799,32882611,Confirmatory,20220830,0,0,Active,0.004000,9606,,
372231041,P07949,GI50,<,ChEMBL,Inhibition of CCDC6-RET fusion protein (unknown origin) expressed in mouse BaF3 cells assessed as reduction in cell proliferation measured after 48 hrs by MTS assay,Pralsetinib,RET - ret proto-oncogene (human),/gene/5979,2.7.10.1,P07949,,,10.1016/j.ejmech.2020.112755,,21684558,"Li X, Su J, Yang Y, Lian W, Deng Z, Yang Z, Chen G, Zhang B, Dong C, Liu X, Li L, Wang Z, Hu Z, Xu Q, Deng X. Discovery of 4-methyl-N-(4-((4-methylpiperazin- 1-yl)methyl)-3-(trifluoromethyl)phenyl)-3-((6-(pyridin-3-yl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl)-oxy)benzamide as a potent inhibitor of RET and its gatekeeper mutant. European Journal of Medicinal Chemistry. 2020 Dec;207():112755. doi: 10.1016/j.ejmech.2020.112755.",1704857,440200762,129073603,483927624,5979,32882611,Confirmatory,20220830,0,0,Active,0.004000,9606,,
373054132,P33176,GI50,<,ChEMBL,Inhibition of KIF5B-RET V804M mutant fusion protein (unknown origin) expressed in mouse BaF3 cells assessed as reduction in cell proliferation measured after 48 hrs by MTS assay,Pralsetinib,KIF5B - kinesin family member 5B (human),/gene/3799,,P33176,,,10.1016/j.ejmech.2020.112755,,21684558,"Li X, Su J, Yang Y, Lian W, Deng Z, Yang Z, Chen G, Zhang B, Dong C, Liu X, Li L, Wang Z, Hu Z, Xu Q, Deng X. Discovery of 4-methyl-N-(4-((4-methylpiperazin- 1-yl)methyl)-3-(trifluoromethyl)phenyl)-3-((6-(pyridin-3-yl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl)-oxy)benzamide as a potent inhibitor of RET and its gatekeeper mutant. European Journal of Medicinal Chemistry. 2020 Dec;207():112755. doi: 10.1016/j.ejmech.2020.112755.",1704862,440200762,129073603,483927624,3799,32882611,Confirmatory,20250102,0,0,Active,0.004000,9606,,
372230456,,GI50,<,ChEMBL,Inhibition of CCDC6-RET V804M mutant fusion protein (unknown origin) expressed in mouse BaF3 cells assessed as reduction in cell proliferation measured after 48 hrs by MTS assay,Pralsetinib,,,,,,,10.1016/j.ejmech.2020.112755,,21684558,"Li X, Su J, Yang Y, Lian W, Deng Z, Yang Z, Chen G, Zhang B, Dong C, Liu X, Li L, Wang Z, Hu Z, Xu Q, Deng X. Discovery of 4-methyl-N-(4-((4-methylpiperazin- 1-yl)methyl)-3-(trifluoromethyl)phenyl)-3-((6-(pyridin-3-yl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl)-oxy)benzamide as a potent inhibitor of RET and its gatekeeper mutant. European Journal of Medicinal Chemistry. 2020 Dec;207():112755. doi: 10.1016/j.ejmech.2020.112755.",1704861,440200762,129073603,483927624,,32882611,Confirmatory,20220830,0,0,Active,0.004000,,,
372230672,P07949,GI50,<,ChEMBL,Inhibition of KIF5B-RET fusion protein (unknown origin) expressed in mouse BaF3 cells assessed as reduction in cell proliferation measured after 48 hrs by MTS assay,Pralsetinib,RET - ret proto-oncogene (human),/gene/5979,2.7.10.1,P07949,,,10.1016/j.ejmech.2020.112755,,21684558,"Li X, Su J, Yang Y, Lian W, Deng Z, Yang Z, Chen G, Zhang B, Dong C, Liu X, Li L, Wang Z, Hu Z, Xu Q, Deng X. Discovery of 4-methyl-N-(4-((4-methylpiperazin- 1-yl)methyl)-3-(trifluoromethyl)phenyl)-3-((6-(pyridin-3-yl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl)-oxy)benzamide as a potent inhibitor of RET and its gatekeeper mutant. European Journal of Medicinal Chemistry. 2020 Dec;207():112755. doi: 10.1016/j.ejmech.2020.112755.",1704858,440200762,129073603,483927624,5979,32882611,Confirmatory,20220830,0,0,Active,0.004000,9606,,
372231042,Q16204,GI50,<,ChEMBL,Inhibition of CCDC6-RET fusion protein (unknown origin) expressed in mouse BaF3 cells assessed as reduction in cell proliferation measured after 48 hrs by MTS assay,Pralsetinib,CCDC6 - coiled-coil domain containing 6 (human),/gene/8030,,Q16204,,,10.1016/j.ejmech.2020.112755,,21684558,"Li X, Su J, Yang Y, Lian W, Deng Z, Yang Z, Chen G, Zhang B, Dong C, Liu X, Li L, Wang Z, Hu Z, Xu Q, Deng X. Discovery of 4-methyl-N-(4-((4-methylpiperazin- 1-yl)methyl)-3-(trifluoromethyl)phenyl)-3-((6-(pyridin-3-yl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl)-oxy)benzamide as a potent inhibitor of RET and its gatekeeper mutant. European Journal of Medicinal Chemistry. 2020 Dec;207():112755. doi: 10.1016/j.ejmech.2020.112755.",1704857,440200762,129073603,483927624,8030,32882611,Confirmatory,20220830,0,0,Active,0.004000,9606,,
383976838,,IC50,=,ChEMBL,Antiproliferative activity against mouse BaF3 cells expressing rearranged during transfection kinase V804L-KIF5B incubated for 74 to 76 hrs by cell counting kit 8 method,Pralsetinib,,,,,,,10.1016/j.ejmech.2022.114862,,35235592,"Zhang Y, Chan S, He R, Liu Y, Song X, Tu Z, Ren X, Zhou Y, Zhang Z, Wang Z, Zhou F, Ding K. 1-Methyl-3-((4-(quinolin-4-yloxy)phenyl)amino)-1H-pyrazole-4-carboxamide derivatives as new rearranged during Transfection (RET) kinase inhibitors capable of suppressing resistant mutants in solvent-front regions. European Journal of Medicinal Chemistry. 2022 Dec;244():114862. doi: 10.1016/j.ejmech.2022.114862.",1946841,440200762,129073603,483927624,,36308779,Confirmatory,20240503,0,0,Active,0.004100,,,
385347525,,IC50,=,ChEMBL,Antiproliferative activity against mouse BaF3 cells expressing CCDC6-RET-V804M incubated for 72 hrs by CCK8 assay,Pralsetinib,,,,,,,10.1016/j.ejmech.2023.115237,,35451621,"Wu K, He R, Li Z, Qiu K, Xiao G, Peng L, Meng X, Zheng C, Zhang Z, Cai Q. Discovery of 3,5-diaryl-1H-pyrazol-based ureas as potent RET inhibitors. European Journal of Medicinal Chemistry. 2023 May;251():115237. doi: 10.1016/j.ejmech.2023.115237.",1995915,404719099,129073603,,,36905915,Confirmatory,20250102,0,0,Active,0.004100,,,
383976505,,IC50,=,ChEMBL,Antiproliferative activity against mouse BaF3 cells expressing wildtype rearranged during transfection kinase-CCDC6 incubated for 74 to 76 hrs by cell counting kit 8 method,Pralsetinib,,,,,,,10.1016/j.ejmech.2022.114862,,35235592,"Zhang Y, Chan S, He R, Liu Y, Song X, Tu Z, Ren X, Zhou Y, Zhang Z, Wang Z, Zhou F, Ding K. 1-Methyl-3-((4-(quinolin-4-yloxy)phenyl)amino)-1H-pyrazole-4-carboxamide derivatives as new rearranged during Transfection (RET) kinase inhibitors capable of suppressing resistant mutants in solvent-front regions. European Journal of Medicinal Chemistry. 2022 Dec;244():114862. doi: 10.1016/j.ejmech.2022.114862.",1946833,440200762,129073603,483927624,,36308779,Confirmatory,20240503,0,0,Active,0.004400,,,
381488192,P07949,IC50,=,ChEMBL,Inhibition of KIF5B-RET (unknown origin) assessed as inhibition of RET autophosphorylation expressed in mouse BaF3 cells,Pralsetinib,RET - ret proto-oncogene (human),/gene/5979,2.7.10.1,P07949,,,10.1021/acs.jmedchem.0c02167,PMC9697126,21703593,"Saha D, Ryan KR, Lakkaniga NR, Acharya B, Garcia NG, Smith EL, Frett B. Targeting Rearranged during Transfection in Cancer: A Perspective on Small-Molecule Inhibitors and Their Clinical Development. J. Med. Chem. 2021 Aug 17;64(16):11747–73. doi: 10.1021/acs.jmedchem.0c02167.",1895764,482048853,129073603,,5979,34402300,Confirmatory,20230629,0,0,Active,0.005000,9606,,
385348101,,IC50,=,ChEMBL,Antiproliferative activity against mouse BaF3 cells expressing CCDC6-RET incubated for 72 hrs by CCK8 assay,Pralsetinib,,,,,,,10.1016/j.ejmech.2023.115237,,35451621,"Wu K, He R, Li Z, Qiu K, Xiao G, Peng L, Meng X, Zheng C, Zhang Z, Cai Q. Discovery of 3,5-diaryl-1H-pyrazol-based ureas as potent RET inhibitors. European Journal of Medicinal Chemistry. 2023 May;251():115237. doi: 10.1016/j.ejmech.2023.115237.",1995914,404719099,129073603,,,36905915,Confirmatory,20250102,0,0,Active,0.005000,,,
381488191,P33176,IC50,=,ChEMBL,Inhibition of KIF5B-RET (unknown origin) assessed as inhibition of RET autophosphorylation expressed in mouse BaF3 cells,Pralsetinib,KIF5B - kinesin family member 5B (human),/gene/3799,,P33176,,,10.1021/acs.jmedchem.0c02167,PMC9697126,21703593,"Saha D, Ryan KR, Lakkaniga NR, Acharya B, Garcia NG, Smith EL, Frett B. Targeting Rearranged during Transfection in Cancer: A Perspective on Small-Molecule Inhibitors and Their Clinical Development. J. Med. Chem. 2021 Aug 17;64(16):11747–73. doi: 10.1021/acs.jmedchem.0c02167.",1895764,482048853,129073603,,3799,34402300,Confirmatory,20230629,0,0,Active,0.005000,9606,,
383976422,,IC50,=,ChEMBL,Antiproliferative activity against mouse BaF3 cells expressing wildtype rearranged during transfection kinase-KIF5B incubated for 74 to 76 hrs by cell counting kit 8 method,Pralsetinib,,,,,,,10.1016/j.ejmech.2022.114862,,35235592,"Zhang Y, Chan S, He R, Liu Y, Song X, Tu Z, Ren X, Zhou Y, Zhang Z, Wang Z, Zhou F, Ding K. 1-Methyl-3-((4-(quinolin-4-yloxy)phenyl)amino)-1H-pyrazole-4-carboxamide derivatives as new rearranged during Transfection (RET) kinase inhibitors capable of suppressing resistant mutants in solvent-front regions. European Journal of Medicinal Chemistry. 2022 Dec;244():114862. doi: 10.1016/j.ejmech.2022.114862.",1946839,440200762,129073603,483927624,,36308779,Confirmatory,20240503,0,0,Active,0.005700,,,
374169673,P36888,IC50,=,ChEMBL,Inhibition of FLT3 (unknown origin),Pralsetinib,FLT3 - fms related receptor tyrosine kinase 3 (human),/gene/2322,2.7.10.1,P36888,,,10.1016/j.bmcl.2021.128149,,2007155,"Luo Z, Wang L, Fu Z, Shuai B, Luo M, Hu G, Chen J, Sun J, Wang J, Li J, Chen S, Zhang Y. Discovery and optimization of selective RET inhibitors via scaffold hopping. Bioorganic & Medicinal Chemistry Letters. 2021 Sep;47():128149. doi: 10.1016/j.bmcl.2021.128149.",1776973,440200762,129073603,483927624,2322,34058344,Confirmatory,20220830,0,0,Active,0.006500,9606,,
383976435,,IC50,=,ChEMBL,Antiproliferative activity against mouse BaF3 cells expressing rearranged during transfection kinase V804M-KIF5B incubated for 74 to 76 hrs by cell counting kit 8 method,Pralsetinib,,,,,,,10.1016/j.ejmech.2022.114862,,35235592,"Zhang Y, Chan S, He R, Liu Y, Song X, Tu Z, Ren X, Zhou Y, Zhang Z, Wang Z, Zhou F, Ding K. 1-Methyl-3-((4-(quinolin-4-yloxy)phenyl)amino)-1H-pyrazole-4-carboxamide derivatives as new rearranged during Transfection (RET) kinase inhibitors capable of suppressing resistant mutants in solvent-front regions. European Journal of Medicinal Chemistry. 2022 Dec;244():114862. doi: 10.1016/j.ejmech.2022.114862.",1946840,440200762,129073603,483927624,,36308779,Confirmatory,20240503,0,0,Active,0.009200,,,
383117587,P07949,IC50,<,BindingDB,RET V804L Gatekeeper Mutant Assay  from US Patent US11279688: 'Inhibitors of RET',Pralsetinib,RET - ret proto-oncogene (human),/gene/5979,2.7.10.1,P07949,,,,,,,1806406,438643802,129073603,,5979,,Confirmatory,20241112,0,0,Active,0.010000,9606,,
383125882,P07949,IC50,<,BindingDB,Biochemical Activity Assay from US Patent US11279688: 'Inhibitors of RET',Pralsetinib,RET - ret proto-oncogene (human),/gene/5979,2.7.10.1,P07949,,,,,,,1806405,438643802,129073603,,5979,,Confirmatory,20241112,0,0,Active,0.010000,9606,,
374169656,,IC50,=,ChEMBL,Antiproliferative activity against mouse KIF5B-RET BaF3 cells by cell based assay,Pralsetinib,,,,,147,,10.1016/j.bmcl.2021.128149,,2007155,"Luo Z, Wang L, Fu Z, Shuai B, Luo M, Hu G, Chen J, Sun J, Wang J, Li J, Chen S, Zhang Y. Discovery and optimization of selective RET inhibitors via scaffold hopping. Bioorganic & Medicinal Chemistry Letters. 2021 Sep;47():128149. doi: 10.1016/j.bmcl.2021.128149.",1776962,440200762,129073603,483927624,,34058344,Confirmatory,20220830,0,0,Active,0.017000,,,
383976685,,IC50,=,ChEMBL,Antiproliferative activity against mouse BaF3 cells expressing rearranged during transfection kinase V804L-G810S incubated for 74 to 76 hrs by cell counting kit 8 method,Pralsetinib,,,,,,,10.1016/j.ejmech.2022.114862,,35235592,"Zhang Y, Chan S, He R, Liu Y, Song X, Tu Z, Ren X, Zhou Y, Zhang Z, Wang Z, Zhou F, Ding K. 1-Methyl-3-((4-(quinolin-4-yloxy)phenyl)amino)-1H-pyrazole-4-carboxamide derivatives as new rearranged during Transfection (RET) kinase inhibitors capable of suppressing resistant mutants in solvent-front regions. European Journal of Medicinal Chemistry. 2022 Dec;244():114862. doi: 10.1016/j.ejmech.2022.114862.",1946843,440200762,129073603,483927624,,36308779,Confirmatory,20240503,0,0,Active,0.021700,,,
381488968,P35968,IC50,=,ChEMBL,Inhibition of recombinant VEGFR2 (unknown origin) incubated for 120 mins by Perkin Elmer electrophoretic mobility shift platform method,Pralsetinib,KDR - kinase insert domain receptor (human),/gene/3791,2.7.10.1,P35968,,,10.1021/acs.jmedchem.0c02167,PMC9697126,21703593,"Saha D, Ryan KR, Lakkaniga NR, Acharya B, Garcia NG, Smith EL, Frett B. Targeting Rearranged during Transfection in Cancer: A Perspective on Small-Molecule Inhibitors and Their Clinical Development. J. Med. Chem. 2021 Aug 17;64(16):11747–73. doi: 10.1021/acs.jmedchem.0c02167.",1895759,482048853,129073603,,3791,34402300,Confirmatory,20230629,0,0,Active,0.035000,9606,,
383117605,P07949,IC50,>,BindingDB,RET V804L Gatekeeper Mutant Assay  from US Patent US11279688: 'Inhibitors of RET',Pralsetinib,RET - ret proto-oncogene (human),/gene/5979,2.7.10.1,P07949,,,,,,,1806406,438643801,129073603,,5979,,Confirmatory,20241112,0,0,Unspecified,0.100000,9606,,
383126040,P07949,IC50,>,BindingDB,Biochemical Activity Assay from US Patent US11279688: 'Inhibitors of RET',Pralsetinib,RET - ret proto-oncogene (human),/gene/5979,2.7.10.1,P07949,,,,,,,1806405,438643801,129073603,,5979,,Confirmatory,20241112,0,0,Unspecified,0.100000,9606,,
385347589,,IC50,=,ChEMBL,Antiproliferative activity against mouse BaF3 cells expressing CCDC6-RET-G810C incubated for 72 hrs by CCK8 assay,Pralsetinib,,,,,,,10.1016/j.ejmech.2023.115237,,35451621,"Wu K, He R, Li Z, Qiu K, Xiao G, Peng L, Meng X, Zheng C, Zhang Z, Cai Q. Discovery of 3,5-diaryl-1H-pyrazol-based ureas as potent RET inhibitors. European Journal of Medicinal Chemistry. 2023 May;251():115237. doi: 10.1016/j.ejmech.2023.115237.",1995916,404719099,129073603,,,36905915,Confirmatory,20250102,0,0,Active,0.114000,,,
383976819,,IC50,=,ChEMBL,Antiproliferative activity against mouse BaF3 cells expressing rearranged during transfection kinase V804L-G810C incubated for 74 to 76 hrs by cell counting kit 8 method,Pralsetinib,,,,,,,10.1016/j.ejmech.2022.114862,,35235592,"Zhang Y, Chan S, He R, Liu Y, Song X, Tu Z, Ren X, Zhou Y, Zhang Z, Wang Z, Zhou F, Ding K. 1-Methyl-3-((4-(quinolin-4-yloxy)phenyl)amino)-1H-pyrazole-4-carboxamide derivatives as new rearranged during Transfection (RET) kinase inhibitors capable of suppressing resistant mutants in solvent-front regions. European Journal of Medicinal Chemistry. 2022 Dec;244():114862. doi: 10.1016/j.ejmech.2022.114862.",1946842,440200762,129073603,483927624,,36308779,Confirmatory,20240503,0,0,Active,0.215000,,,
383976669,,IC50,=,ChEMBL,Antiproliferative activity against mouse BaF3 cells expressing rearranged during transfection kinase V804L-G810R incubated for 74 to 76 hrs by cell counting kit 8 method,Pralsetinib,,,,,,,10.1016/j.ejmech.2022.114862,,35235592,"Zhang Y, Chan S, He R, Liu Y, Song X, Tu Z, Ren X, Zhou Y, Zhang Z, Wang Z, Zhou F, Ding K. 1-Methyl-3-((4-(quinolin-4-yloxy)phenyl)amino)-1H-pyrazole-4-carboxamide derivatives as new rearranged during Transfection (RET) kinase inhibitors capable of suppressing resistant mutants in solvent-front regions. European Journal of Medicinal Chemistry. 2022 Dec;244():114862. doi: 10.1016/j.ejmech.2022.114862.",1946844,440200762,129073603,483927624,,36308779,Confirmatory,20240503,0,0,Active,0.241000,,,
383976720,,IC50,>,ChEMBL,Antiproliferative activity against mouse BaF3 cells expressing rearranged during transfection kinase G810C-CCDC6 incubated for 74 to 76 hrs by cell counting kit 8 method,Pralsetinib,,,,,,,10.1016/j.ejmech.2022.114862,,35235592,"Zhang Y, Chan S, He R, Liu Y, Song X, Tu Z, Ren X, Zhou Y, Zhang Z, Wang Z, Zhou F, Ding K. 1-Methyl-3-((4-(quinolin-4-yloxy)phenyl)amino)-1H-pyrazole-4-carboxamide derivatives as new rearranged during Transfection (RET) kinase inhibitors capable of suppressing resistant mutants in solvent-front regions. European Journal of Medicinal Chemistry. 2022 Dec;244():114862. doi: 10.1016/j.ejmech.2022.114862.",1946836,440200762,129073603,483927624,,36308779,Confirmatory,20240503,0,0,Unspecified,0.261000,,,
385347563,,IC50,=,ChEMBL,Antiproliferative activity against mouse BaF3 cells expressing CCDC6-RET-G810R incubated for 72 hrs by CCK8 assay,Pralsetinib,,,,,,,10.1016/j.ejmech.2023.115237,,35451621,"Wu K, He R, Li Z, Qiu K, Xiao G, Peng L, Meng X, Zheng C, Zhang Z, Cai Q. Discovery of 3,5-diaryl-1H-pyrazol-based ureas as potent RET inhibitors. European Journal of Medicinal Chemistry. 2023 May;251():115237. doi: 10.1016/j.ejmech.2023.115237.",1995917,404719099,129073603,,,36905915,Confirmatory,20250102,0,0,Active,0.358000,,,
381488144,,IC50,>,ChEMBL,Inhibition of RET G810R (unknown origin),Pralsetinib,,,,,,,10.1021/acs.jmedchem.0c02167,PMC9697126,21703593,"Saha D, Ryan KR, Lakkaniga NR, Acharya B, Garcia NG, Smith EL, Frett B. Targeting Rearranged during Transfection in Cancer: A Perspective on Small-Molecule Inhibitors and Their Clinical Development. J. Med. Chem. 2021 Aug 17;64(16):11747–73. doi: 10.1021/acs.jmedchem.0c02167.",1895765,482048853,129073603,,,34402300,Confirmatory,20230629,0,0,Unspecified,0.500000,,,
382870816,P07949,IC50,<,BindingDB,RET Wild Type Assay at KM from US Patent US10584114: 'Inhibitors of RET',Pralsetinib,RET - ret proto-oncogene (human),/gene/5979,2.7.10.1,P07949,,,,,,,1804253,438643802,129073603,,5979,,Confirmatory,20241112,0,0,Active,0.500000,9606,,
382871928,P07949,IC50,<,BindingDB,RET V804L Gatekeeper Mutant Assay at KM from US Patent US10584114: 'Inhibitors of RET',Pralsetinib,RET - ret proto-oncogene (human),/gene/5979,2.7.10.1,P07949,,,,,,,1804254,438643802,129073603,,5979,,Confirmatory,20241112,0,0,Active,0.500000,9606,,
383976530,,IC50,=,ChEMBL,Antiproliferative activity against mouse BaF3 cells expressing rearranged during transfection kinase G810R-CCDC6 incubated for 74 to 76 hrs by cell counting kit 8 method,Pralsetinib,,,,,,,10.1016/j.ejmech.2022.114862,,35235592,"Zhang Y, Chan S, He R, Liu Y, Song X, Tu Z, Ren X, Zhou Y, Zhang Z, Wang Z, Zhou F, Ding K. 1-Methyl-3-((4-(quinolin-4-yloxy)phenyl)amino)-1H-pyrazole-4-carboxamide derivatives as new rearranged during Transfection (RET) kinase inhibitors capable of suppressing resistant mutants in solvent-front regions. European Journal of Medicinal Chemistry. 2022 Dec;244():114862. doi: 10.1016/j.ejmech.2022.114862.",1946837,440200762,129073603,483927624,,36308779,Confirmatory,20240503,0,0,Active,0.575000,,,
385348478,,IC50,=,ChEMBL,Antiproliferative activity against mouse BaF3 cells incubated for 72 hrs by CCK8 assay,Pralsetinib,,,,,,,10.1016/j.ejmech.2023.115237,,35451621,"Wu K, He R, Li Z, Qiu K, Xiao G, Peng L, Meng X, Zheng C, Zhang Z, Cai Q. Discovery of 3,5-diaryl-1H-pyrazol-based ureas as potent RET inhibitors. European Journal of Medicinal Chemistry. 2023 May;251():115237. doi: 10.1016/j.ejmech.2023.115237.",1995918,404719099,129073603,,,36905915,Confirmatory,20250102,0,0,Active,1.040000,,,
383976801,,IC50,=,ChEMBL,Antiproliferative activity against mouse BaF3 cells incubated for 74 to 76 hrs by cell counting kit 8 method,Pralsetinib,,,,,,,10.1016/j.ejmech.2022.114862,,35235592,"Zhang Y, Chan S, He R, Liu Y, Song X, Tu Z, Ren X, Zhou Y, Zhang Z, Wang Z, Zhou F, Ding K. 1-Methyl-3-((4-(quinolin-4-yloxy)phenyl)amino)-1H-pyrazole-4-carboxamide derivatives as new rearranged during Transfection (RET) kinase inhibitors capable of suppressing resistant mutants in solvent-front regions. European Journal of Medicinal Chemistry. 2022 Dec;244():114862. doi: 10.1016/j.ejmech.2022.114862.",1946838,440200762,129073603,483927624,,36308779,Confirmatory,20240503,0,0,Active,1.170000,,,
372230035,,GI50,=,ChEMBL,Cytotoxicity against mouse BaF3 cells assessed as reduction in cell proliferation measured after 48 hrs by MTS assay,Pralsetinib,,,,,147,,10.1016/j.ejmech.2020.112755,,21684558,"Li X, Su J, Yang Y, Lian W, Deng Z, Yang Z, Chen G, Zhang B, Dong C, Liu X, Li L, Wang Z, Hu Z, Xu Q, Deng X. Discovery of 4-methyl-N-(4-((4-methylpiperazin- 1-yl)methyl)-3-(trifluoromethyl)phenyl)-3-((6-(pyridin-3-yl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl)-oxy)benzamide as a potent inhibitor of RET and its gatekeeper mutant. European Journal of Medicinal Chemistry. 2020 Dec;207():112755. doi: 10.1016/j.ejmech.2020.112755.",1704863,440200762,129073603,483927624,,32882611,Confirmatory,20220830,0,0,Active,1.266000,,,
382871107,P07949,IC50,,BindingDB,RET Wild Type Assay at KM from US Patent US10584114: 'Inhibitors of RET',Pralsetinib,RET - ret proto-oncogene (human),/gene/5979,2.7.10.1,P07949,,,,,,,1804253,438643801,129073603,,5979,,Confirmatory,20241112,0,0,Active,6.000000,9606,,
382871816,P07949,IC50,,BindingDB,RET V804L Gatekeeper Mutant Assay at KM from US Patent US10584114: 'Inhibitors of RET',Pralsetinib,RET - ret proto-oncogene (human),/gene/5979,2.7.10.1,P07949,,,,,,,1804254,438643801,129073603,,5979,,Confirmatory,20241112,0,0,Active,6.000000,9606,,
374231874,,Cp,=,ChEMBL,"Drug level in plasma of mouse transplanted with mouse KIF5B-RET Ba/F3 cells at 10 mg/kg, po qd for 10 days measured after 8.5 hrs",Pralsetinib,,,,,147,Plasma,10.1016/j.bmcl.2021.128149,,2007155,"Luo Z, Wang L, Fu Z, Shuai B, Luo M, Hu G, Chen J, Sun J, Wang J, Li J, Chen S, Zhang Y. Discovery and optimization of selective RET inhibitors via scaffold hopping. Bioorganic & Medicinal Chemistry Letters. 2021 Sep;47():128149. doi: 10.1016/j.bmcl.2021.128149.",1776975,440200762,129073603,483927624,,34058344,Confirmatory,20230629,0,0,Active,6.315000,,,1969
384515827,,IC50 relative,=,ChEMBL,Cytotoxicity activity against human HepG2 cells assessed by CellTiter-Glo luminescent cell viability assay.,Pralsetinib,,,,,27,,,,,,1962016,440200762,129073603,483927624,,,Confirmatory,20250102,0,0,Active,9.300000,,,
107160676,,,,DTP/NCI,NCI human tumor cell line growth inhibition assay. Data for the NCI-H226 Non-Small Cell Lung cell line,Pralsetinib,,,,,4004,,,,,,3,440795530,129073603,,,,Confirmatory,20250721,0,0,Active,,,,
107190028,,,,DTP/NCI,NCI human tumor cell line growth inhibition assay. Data for the A549/ATCC Non-Small Cell Lung cell line,Pralsetinib,,,,,23,,,,,,19,440795530,129073603,,,,Confirmatory,20250721,0,0,Inactive,,,,
107129584,,,,DTP/NCI,NCI human tumor cell line growth inhibition assay. Data for the NCI-H522 Non-Small Cell Lung cell line,Pralsetinib,,,,,4027,,,,,,15,440795530,129073603,,,,Confirmatory,20250721,0,0,Inactive,,,,
107066562,,,,DTP/NCI,NCI human tumor cell line growth inhibition assay. Data for the M14 Melanoma cell line,Pralsetinib,,,,,3858,,,,,,25,440795530,129073603,,,,Confirmatory,20250721,0,0,Inactive,,,,
106856791,,,,DTP/NCI,NCI human tumor cell line growth inhibition assay. Data for the UACC-257 Melanoma cell line,Pralsetinib,,,,,4235,,,,,,33,440795530,129073603,,,,Confirmatory,20250721,0,0,Inactive,,,,
107130174,,,,DTP/NCI,NCI human tumor cell line growth inhibition assay. Data for the HOP-92 Non-Small Cell Lung cell line,Pralsetinib,,,,,3749,,,,,,13,440795530,129073603,,,,Confirmatory,20250721,0,0,Inactive,,,,
107210226,,,,DTP/NCI,NCI human tumor cell line growth inhibition assay. Data for the NCI-H460 Non-Small Cell Lung cell line,Pralsetinib,,,,,431,,,,,,7,440795530,129073603,,,,Confirmatory,20250721,0,0,Inactive,,,,
106807407,,,,DTP/NCI,NCI human tumor cell line growth inhibition assay. Data for the DU-145 Prostate cell line,Pralsetinib,,,,,94,,,,,,43,440795530,129073603,,,,Confirmatory,20250721,0,0,Inactive,,,,
107034010,,,,DTP/NCI,NCI human tumor cell line growth inhibition assay. Data for the SK-MEL-2 Melanoma cell line,Pralsetinib,,,,,59,,,,,,35,440795530,129073603,,,,Confirmatory,20250721,0,0,Inactive,,,,
106694152,,,,DTP/NCI,NCI human tumor cell line growth inhibition assay. Data for the PC-3 Prostate cell line,Pralsetinib,,,,,35,,,,,,41,440795530,129073603,,,,Confirmatory,20250721,0,0,Inactive,,,,
109600990,,,,DTP/NCI,NCI human tumor cell line growth inhibition assay. Data for the RPMI-8226 Leukemia cell line,Pralsetinib,,,,,14,,,,,,113,440795530,129073603,,,,Confirmatory,20250721,0,0,Inactive,,,,
106959374,,,,DTP/NCI,NCI human tumor cell line growth inhibition assay. Data for the SK-MEL-28 Melanoma cell line,Pralsetinib,,,,,498,,,,,,39,440795530,129073603,,,,Confirmatory,20250721,0,0,Inactive,,,,
109478388,,,,DTP/NCI,NCI human tumor cell line growth inhibition assay. Data for the CAKI-1 Renal cell line,Pralsetinib,,,,,216,,,,,,131,440795530,129073603,,,,Confirmatory,20250721,0,0,Inactive,,,,
106996432,,,,DTP/NCI,NCI human tumor cell line growth inhibition assay. Data for the SK-MEL-5 Melanoma cell line,Pralsetinib,,,,,499,,,,,,37,440795530,129073603,,,,Confirmatory,20250721,0,0,Inactive,,,,
109516016,,,,DTP/NCI,NCI human tumor cell line growth inhibition assay. Data for the MOLT-4 Leukemia cell line,Pralsetinib,,,,,13,,,,,,123,440795530,129073603,,,,Confirmatory,20250721,0,0,Inactive,,,,
107807824,,,,DTP/NCI,NCI human tumor cell line growth inhibition assay. Data for the MDA-MB-231/ATCC Breast cell line,Pralsetinib,,,,,53,,,,,,95,440795530,129073603,,,,Confirmatory,20250721,0,0,Inactive,,,,
109576810,,,,DTP/NCI,NCI human tumor cell line growth inhibition assay. Data for the CCRF-CEM Leukemia cell line,Pralsetinib,,,,,191,,,,,,119,440795530,129073603,,,,Confirmatory,20250721,0,0,Inactive,,,,
109699624,,,,DTP/NCI,NCI human tumor cell line growth inhibition assay. Data for the SK-OV-3 Ovarian cell line,Pralsetinib,,,,,504,,,,,,103,440795530,129073603,,,,Confirmatory,20250721,0,0,Inactive,,,,
107728047,,,,DTP/NCI,NCI human tumor cell line growth inhibition assay. Data for the HS 578T Breast cell line,Pralsetinib,,,,,310,,,,,,97,440795530,129073603,,,,Confirmatory,20250721,0,0,Active,,,,
108157222,,,,DTP/NCI,NCI human tumor cell line growth inhibition assay. Data for the HCC-2998 Colon cell line,Pralsetinib,,,,,3729,,,,,,77,440795530,129073603,,,,Confirmatory,20250721,0,0,Inactive,,,,
374231608,,,,ChEMBL,"AUC in mouse plasma at 10 mg/kg, po",Pralsetinib,,,,,,Plasma,10.1016/j.bmcl.2021.128149,,2007155,"Luo Z, Wang L, Fu Z, Shuai B, Luo M, Hu G, Chen J, Sun J, Wang J, Li J, Chen S, Zhang Y. Discovery and optimization of selective RET inhibitors via scaffold hopping. Bioorganic & Medicinal Chemistry Letters. 2021 Sep;47():128149. doi: 10.1016/j.bmcl.2021.128149.",1776966,440200762,129073603,483927624,,34058344,Literature-derived,20230629,0,0,Unspecified,,,,1969
109632641,,,,DTP/NCI,NCI human tumor cell line growth inhibition assay. Data for the OVCAR-4 Ovarian cell line,Pralsetinib,,,,,4087,,,,,,105,440795530,129073603,,,,Confirmatory,20250721,0,0,Inactive,,,,
109609367,,,,DTP/NCI,NCI human tumor cell line growth inhibition assay. Data for the OVCAR-8 Ovarian cell line,Pralsetinib,,,,,4089,,,,,,109,440795530,129073603,,,,Confirmatory,20250721,0,0,Inactive,,,,
109637633,,,,DTP/NCI,NCI human tumor cell line growth inhibition assay. Data for the OVCAR-5 Ovarian cell line,Pralsetinib,,,,,4088,,,,,,107,440795530,129073603,,,,Confirmatory,20250721,0,0,Inactive,,,,
109757981,,,,DTP/NCI,NCI human tumor cell line growth inhibition assay. Data for the OVCAR-3 Ovarian cell line,Pralsetinib,,,,,437,,,,,,99,440795530,129073603,,,,Confirmatory,20250721,0,0,Inactive,,,,
374169808,,,,ChEMBL,"Toxicity in mouse transplanted with mouse KIF5B-RET Ba/F3 cells assessed as change in body weight at 10 mg/kg, po bid for 10 days relative to control",Pralsetinib,,,,,147,,10.1016/j.bmcl.2021.128149,,2007155,"Luo Z, Wang L, Fu Z, Shuai B, Luo M, Hu G, Chen J, Sun J, Wang J, Li J, Chen S, Zhang Y. Discovery and optimization of selective RET inhibitors via scaffold hopping. Bioorganic & Medicinal Chemistry Letters. 2021 Sep;47():128149. doi: 10.1016/j.bmcl.2021.128149.",1776970,440200762,129073603,483927624,,34058344,Literature-derived,20220830,0,0,Unspecified,,,,
374169848,,,,ChEMBL,Intrinsic clearance in human liver microsomes,Pralsetinib,,,,,,Liver,10.1016/j.bmcl.2021.128149,,2007155,"Luo Z, Wang L, Fu Z, Shuai B, Luo M, Hu G, Chen J, Sun J, Wang J, Li J, Chen S, Zhang Y. Discovery and optimization of selective RET inhibitors via scaffold hopping. Bioorganic & Medicinal Chemistry Letters. 2021 Sep;47():128149. doi: 10.1016/j.bmcl.2021.128149.",1776974,440200762,129073603,483927624,,34058344,Literature-derived,20220830,0,0,Unspecified,,,,2107
374170038,,,,ChEMBL,"Antitumor activity against mouse KIF5B-RET BaF3 cells xenografted in nu/nu mouse assessed as tumour growth inhibition at 10 mg/kg, po qd for 10 days",Pralsetinib,,,,,147,,10.1016/j.bmcl.2021.128149,,2007155,"Luo Z, Wang L, Fu Z, Shuai B, Luo M, Hu G, Chen J, Sun J, Wang J, Li J, Chen S, Zhang Y. Discovery and optimization of selective RET inhibitors via scaffold hopping. Bioorganic & Medicinal Chemistry Letters. 2021 Sep;47():128149. doi: 10.1016/j.bmcl.2021.128149.",1776968,440200762,129073603,483927624,,34058344,Literature-derived,20220830,0,0,Active,,,,
374170346,,,,ChEMBL,Oral bioavailability in mouse,Pralsetinib,,,,,,,10.1016/j.bmcl.2021.128149,,2007155,"Luo Z, Wang L, Fu Z, Shuai B, Luo M, Hu G, Chen J, Sun J, Wang J, Li J, Chen S, Zhang Y. Discovery and optimization of selective RET inhibitors via scaffold hopping. Bioorganic & Medicinal Chemistry Letters. 2021 Sep;47():128149. doi: 10.1016/j.bmcl.2021.128149.",1776967,440200762,129073603,483927624,,34058344,Literature-derived,20220830,0,0,Unspecified,,,,
109840391,,,,DTP/NCI,NCI human tumor cell line growth inhibition assay. Data for the SN12C Renal cell line,Pralsetinib,,,,,4163,,,,,,145,440795530,129073603,,,,Confirmatory,20250721,0,0,Inactive,,,,
109914753,,,,DTP/NCI,NCI human tumor cell line growth inhibition assay. Data for the MDA-MB-435 Breast cell line,Pralsetinib,,,,,394,,,,,,85,440795530,129073603,,,,Confirmatory,20250721,0,0,Inactive,,,,
374171086,,,,ChEMBL,Volume of distribution in mouse,Pralsetinib,,,,,,,10.1016/j.bmcl.2021.128149,,2007155,"Luo Z, Wang L, Fu Z, Shuai B, Luo M, Hu G, Chen J, Sun J, Wang J, Li J, Chen S, Zhang Y. Discovery and optimization of selective RET inhibitors via scaffold hopping. Bioorganic & Medicinal Chemistry Letters. 2021 Sep;47():128149. doi: 10.1016/j.bmcl.2021.128149.",1776965,440200762,129073603,483927624,,34058344,Literature-derived,20220830,0,0,Unspecified,,,,
374171270,,,,ChEMBL,Clearance in mouse,Pralsetinib,,,,,,,10.1016/j.bmcl.2021.128149,,2007155,"Luo Z, Wang L, Fu Z, Shuai B, Luo M, Hu G, Chen J, Sun J, Wang J, Li J, Chen S, Zhang Y. Discovery and optimization of selective RET inhibitors via scaffold hopping. Bioorganic & Medicinal Chemistry Letters. 2021 Sep;47():128149. doi: 10.1016/j.bmcl.2021.128149.",1776964,440200762,129073603,483927624,,34058344,Literature-derived,20220830,0,0,Unspecified,,,,
392014770,Q8JUX6,Potency,,National Center for Advancing Translational Sciences (NCATS),Primary qHTS for inhibitors of NSP2Pro chikungunya virus (CHIKV),Pralsetinib,Polyprotein P1234 (Chikungunya virus strain S27-African prototype),/protein/Q8JUX6,2.1.1.-|2.7.7.-|2.7.7.19|2.7.7.48|3.1.3.84|3.4.22.-|3.6.1.15|3.6.1.74|3.6.4.13,Q8JUX6,,,,,,,1964107,504066034,129073603,,,,Confirmatory,20250718,1,0,Inactive,,371094,,
109851063,,,,DTP/NCI,NCI human tumor cell line growth inhibition assay. Data for the NCI/ADR-RES Breast cell line,Pralsetinib,,,,,3912,,,,,,93,440795530,129073603,,,,Confirmatory,20250721,0,0,Inactive,,,,
374170465,,,,ChEMBL,Intrinsic clearance in mouse liver microsomes,Pralsetinib,,,,,,Liver,10.1016/j.bmcl.2021.128149,,2007155,"Luo Z, Wang L, Fu Z, Shuai B, Luo M, Hu G, Chen J, Sun J, Wang J, Li J, Chen S, Zhang Y. Discovery and optimization of selective RET inhibitors via scaffold hopping. Bioorganic & Medicinal Chemistry Letters. 2021 Sep;47():128149. doi: 10.1016/j.bmcl.2021.128149.",1776963,440200762,129073603,483927624,,34058344,Literature-derived,20220830,0,0,Unspecified,,,,2107
374170551,,,,ChEMBL,"Drug level in tumor of mouse transplanted with mouse KIF5B-RET Ba/F3 cells at 10 mg/kg, po qd for 10 days measured after 8.5 hrs",Pralsetinib,,,,,147,Neoplasm,10.1016/j.bmcl.2021.128149,,2007155,"Luo Z, Wang L, Fu Z, Shuai B, Luo M, Hu G, Chen J, Sun J, Wang J, Li J, Chen S, Zhang Y. Discovery and optimization of selective RET inhibitors via scaffold hopping. Bioorganic & Medicinal Chemistry Letters. 2021 Sep;47():128149. doi: 10.1016/j.bmcl.2021.128149.",1776976,440200762,129073603,483927624,,34058344,Literature-derived,20220830,0,0,Unspecified,,,,10000016
107061563,,,,DTP/NCI,NCI human tumor cell line growth inhibition assay. Data for the MALME-3M Melanoma cell line,Pralsetinib,,,,,3901,,,,,,29,440795530,129073603,,,,Confirmatory,20250721,0,0,Inactive,,,,
109408038,,,,DTP/NCI,NCI human tumor cell line growth inhibition assay. Data for the RXF 393 Renal cell line,Pralsetinib,,,,,4132,,,,,,133,440795530,129073603,,,,Confirmatory,20250721,0,0,Active,,,,
109222744,,,,DTP/NCI,NCI human tumor cell line growth inhibition assay. Data for the 786-0 Renal cell line,Pralsetinib,,,,,3514,,,,,,137,440795530,129073603,,,,Confirmatory,20250721,0,0,Inactive,,,,
109421248,,,,DTP/NCI,NCI human tumor cell line growth inhibition assay. Data for the A498 Renal cell line,Pralsetinib,,,,,3519,,,,,,129,440795530,129073603,,,,Confirmatory,20250721,0,0,Active,,,,
107085747,,,,DTP/NCI,NCI human tumor cell line growth inhibition assay. Data for the LOX IMVI Melanoma cell line,Pralsetinib,,,,,3844,,,,,,23,440795530,129073603,,,,Confirmatory,20250721,0,0,Inactive,,,,
381488124,P07949,,,ChEMBL,"Potency index, ratio of -agerafenib IC50 to test compound IC50 for inhibition of wildtype RET ((unknown origin)",Pralsetinib,RET - ret proto-oncogene (human),/gene/5979,2.7.10.1,P07949,,,10.1021/acs.jmedchem.0c02167,PMC9697126,21703593,"Saha D, Ryan KR, Lakkaniga NR, Acharya B, Garcia NG, Smith EL, Frett B. Targeting Rearranged during Transfection in Cancer: A Perspective on Small-Molecule Inhibitors and Their Clinical Development. J. Med. Chem. 2021 Aug 17;64(16):11747–73. doi: 10.1021/acs.jmedchem.0c02167.",1895763,482048853,129073603,,5979,34402300,Literature-derived,20230629,0,0,Unspecified,,9606,,
381488346,P07949,,,ChEMBL,"Potency index, ratio of cabozantinib IC50 to test compound IC50 for inhibition of wildtype RET ((unknown origin)",Pralsetinib,RET - ret proto-oncogene (human),/gene/5979,2.7.10.1,P07949,,,10.1021/acs.jmedchem.0c02167,PMC9697126,21703593,"Saha D, Ryan KR, Lakkaniga NR, Acharya B, Garcia NG, Smith EL, Frett B. Targeting Rearranged during Transfection in Cancer: A Perspective on Small-Molecule Inhibitors and Their Clinical Development. J. Med. Chem. 2021 Aug 17;64(16):11747–73. doi: 10.1021/acs.jmedchem.0c02167.",1895761,482048853,129073603,,5979,34402300,Literature-derived,20230629,0,0,Unspecified,,9606,,
107088365,,,,DTP/NCI,NCI human tumor cell line growth inhibition assay. Data for the EKVX Non-Small Cell Lung cell line,Pralsetinib,,,,,3658,,,,,,21,440795530,129073603,,,,Confirmatory,20250721,0,0,Inactive,,,,
107036329,,,,DTP/NCI,NCI human tumor cell line growth inhibition assay. Data for the UACC-62 Melanoma cell line,Pralsetinib,,,,,4236,,,,,,31,440795530,129073603,,,,Confirmatory,20250721,0,0,Inactive,,,,
107256782,,,,DTP/NCI,NCI human tumor cell line growth inhibition assay. Data for the NCI-H23 Non-Small Cell Lung cell line,Pralsetinib,,,,,4007,,,,,,1,440795530,129073603,,,,Confirmatory,20250721,0,0,Inactive,,,,
109522581,,,,DTP/NCI,NCI human tumor cell line growth inhibition assay. Data for the K-562 Leukemia cell line,Pralsetinib,,,,,4,,,,,,121,440795530,129073603,,,,Confirmatory,20250721,0,0,Inactive,,,,
109482097,,,,DTP/NCI,NCI human tumor cell line growth inhibition assay. Data for the HL-60(TB) Leukemia cell line,Pralsetinib,,,,,2,,,,,,125,440795530,129073603,,,,Confirmatory,20250721,0,0,Inactive,,,,
109564697,,,,DTP/NCI,NCI human tumor cell line growth inhibition assay. Data for the SR Leukemia cell line,Pralsetinib,,,,,4169,,,,,,115,440795530,129073603,,,,Confirmatory,20250721,0,0,Inactive,,,,
397634140,,,,DTP/NCI,NCI human tumor cell line growth inhibition assay. Data for the MDA-MB-468 Non-Small Cell Lung cell line,Pralsetinib,,,,,,,,,,,2202373,440795530,129073603,,,,Confirmatory,20260120,0,0,Inactive,,,,
108653049,,,,DTP/NCI,NCI human tumor cell line growth inhibition assay. Data for the SF-295 Central Nervous System cell line,Pralsetinib,,,,,4149,,,,,,47,440795530,129073603,,,,Confirmatory,20250721,0,0,Inactive,,,,
108786333,,,,DTP/NCI,NCI human tumor cell line growth inhibition assay. Data for the UO-31 Renal cell line,Pralsetinib,,,,,4367,,,,,,143,440795530,129073603,,,,Confirmatory,20250721,0,0,Inactive,,,,
108603371,,,,DTP/NCI,NCI human tumor cell line growth inhibition assay. Data for the HT29 Colon cell line,Pralsetinib,,,,,298,,,,,,65,440795530,129073603,,,,Confirmatory,20250721,0,0,Inactive,,,,
108800207,,,,DTP/NCI,NCI human tumor cell line growth inhibition assay. Data for the TK-10 Renal cell line,Pralsetinib,,,,,4230,,,,,,141,440795530,129073603,,,,Confirmatory,20250721,0,0,Inactive,,,,
108635361,,,,DTP/NCI,NCI human tumor cell line growth inhibition assay. Data for the SNB-19 Central Nervous System cell line,Pralsetinib,,,,,507,,,,,,53,440795530,129073603,,,,Confirmatory,20250721,0,0,Inactive,,,,
109193916,,,,DTP/NCI,NCI human tumor cell line growth inhibition assay. Data for the ACHN Renal cell line,Pralsetinib,,,,,3530,,,,,,139,440795530,129073603,,,,Confirmatory,20250721,0,0,Inactive,,,,
107229483,,,,DTP/NCI,NCI human tumor cell line growth inhibition assay. Data for the HOP-62 Non-Small Cell Lung cell line,Pralsetinib,,,,,3748,,,,,,9,440795530,129073603,,,,Confirmatory,20250721,0,0,Inactive,,,,
108357923,,,,DTP/NCI,NCI human tumor cell line growth inhibition assay. Data for the KM12 Colon cell line,Pralsetinib,,,,,3794,,,,,,73,440795530,129073603,,,,Confirmatory,20250721,0,0,Active,,,,
107994041,,,,DTP/NCI,NCI human tumor cell line growth inhibition assay. Data for the BT-549 Breast cell line,Pralsetinib,,,,,3555,,,,,,89,440795530,129073603,,,,Confirmatory,20250721,0,0,Inactive,,,,
107957257,,,,DTP/NCI,NCI human tumor cell line growth inhibition assay. Data for the T-47D Breast cell line,Pralsetinib,,,,,525,,,,,,91,440795530,129073603,,,,Confirmatory,20250721,0,0,Inactive,,,,
108071373,,,,DTP/NCI,NCI human tumor cell line growth inhibition assay. Data for the MCF7 Breast cell line,Pralsetinib,,,,,31,,,,,,83,440795530,129073603,,,,Confirmatory,20250721,0,0,Inactive,,,,
108255485,,,,DTP/NCI,NCI human tumor cell line growth inhibition assay. Data for the HCT-116 Colon cell line,Pralsetinib,,,,,269,,,,,,79,440795530,129073603,,,,Confirmatory,20250721,0,0,Inactive,,,,
108624004,,,,DTP/NCI,NCI human tumor cell line growth inhibition assay. Data for the U251 Central Nervous System cell line,Pralsetinib,,,,,21,,,,,,59,440795530,129073603,,,,Confirmatory,20250727,0,0,Inactive,,,,
108627982,,,,DTP/NCI,NCI human tumor cell line growth inhibition assay. Data for the SNB-75 Central Nervous System cell line,Pralsetinib,,,,,4164,,,,,,55,440795530,129073603,,,,Confirmatory,20250721,0,0,Active,,,,
108527156,,,,DTP/NCI,NCI human tumor cell line growth inhibition assay. Data for the HCT-15 Colon cell line,Pralsetinib,,,,,270,,,,,,71,440795530,129073603,,,,Confirmatory,20250721,0,0,Inactive,,,,
108641472,,,,DTP/NCI,NCI human tumor cell line growth inhibition assay. Data for the SF-268 Central Nervous System cell line,Pralsetinib,,,,,4148,,,,,,45,440795530,129073603,,,,Confirmatory,20250721,0,0,Inactive,,,,
108647928,,,,DTP/NCI,NCI human tumor cell line growth inhibition assay. Data for the SF-539 Central Nervous System cell line,Pralsetinib,,,,,4150,,,,,,49,440795530,129073603,,,,Confirmatory,20250721,0,0,Active,,,,
108231351,,,,DTP/NCI,NCI human tumor cell line growth inhibition assay. Data for the SW-620 Colon cell line,Pralsetinib,,,,,519,,,,,,81,440795530,129073603,,,,Confirmatory,20250721,0,0,Inactive,,,,
108594878,,,,DTP/NCI,NCI human tumor cell line growth inhibition assay. Data for the COLO 205 Colon cell line,Pralsetinib,,,,,202,,,,,,67,440795530,129073603,,,,Confirmatory,20250721,0,0,Inactive,,,,
388554976,P0DTD1,,,ChEMBL,SARS-CoV-2 3CL-Pro protease inhibition percentage at 20µM  by FRET kind of response from peptide substrate,Pralsetinib,Replicase polyprotein 1ab (Severe acute respiratory syndrome coronavirus 2),/protein/P0DTD1,2.1.1.56|2.1.1.57|2.7.7.48|2.7.7.50|3.1.13.-|3.4.19.12|3.4.22.-|3.4.22.69|3.6.4.12|3.6.4.13|4.6.1.-,P0DTD1,,,,,,,1640020,440200762,129073603,483927624,,,Other,20250102,0,0,Unspecified,,2697049,,
381488347,P07949,,,ChEMBL,"Potency index, ratio of -vandetanib IC50 to test compound IC50 for inhibition of wildtype RET ((unknown origin)",Pralsetinib,RET - ret proto-oncogene (human),/gene/5979,2.7.10.1,P07949,,,10.1021/acs.jmedchem.0c02167,PMC9697126,21703593,"Saha D, Ryan KR, Lakkaniga NR, Acharya B, Garcia NG, Smith EL, Frett B. Targeting Rearranged during Transfection in Cancer: A Perspective on Small-Molecule Inhibitors and Their Clinical Development. J. Med. Chem. 2021 Aug 17;64(16):11747–73. doi: 10.1021/acs.jmedchem.0c02167.",1895762,482048853,129073603,,5979,34402300,Literature-derived,20230629,0,0,Unspecified,,9606,,
388561184,,,,ChEMBL,Antiviral activity determined as inhibition of SARS-CoV-2 induced cytotoxicity of VERO-6 cells at 10 uM after 48 hours exposure to 0.01 MOI SARS CoV-2 virus by high content imaging,Pralsetinib,Severe acute respiratory syndrome coronavirus 2,/taxonomy/2697049,,,546,,,,,,1645758,440200762,129073603,483927624,,,Other,20250102,0,0,Unspecified,,2697049,2697049,
388561183,,,,ChEMBL,Antiviral activity determined as inhibition of SARS-CoV-2 induced cytotoxicity of VERO-6 cells at 10 uM after 48 hours exposure to 0.01 MOI SARS CoV-2 virus by high content imaging,Pralsetinib,Severe acute respiratory syndrome coronavirus 2,/taxonomy/2697049,,,546,,,,,,1645758,440200762,129073603,483927624,,,Other,20250102,0,0,Unspecified,,2697049,2697049,
